Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$104.77 USD

104.77
19,451,666

-0.47 (-0.45%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $104.41 -0.36 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ABT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Abbott Laboratories [ABT]

Reports for Purchase

Showing records 461 - 480 ( 534 total )

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 461

02/24/2012

Company Report

Pages: 9

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 462

01/27/2012

Company Report

Pages: 10

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 463

01/26/2012

Company Report

Pages: 10

Sales Held Back by Less Favorable Currency Trends and Slowing Vascular Revenue

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 464

12/05/2011

Industry Report

Pages: 4

With RAC Prepayment Audit Pressures Systemic, We Continue to Prefer STJ On Steady Share Gains & SYK Given Diversified Footprint

Provider: KAUFMAN BROTHERS

Analyst: CERVANTES V

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 465

12/05/2011

Daily Note

Pages: 4

In Today''s Morning Exchange

Provider: KAUFMAN BROTHERS

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 466

12/02/2011

Company Report

Pages: 9

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 467

11/07/2011

Industry Report

Pages: 11

Life Sciences -2011 ASH PLANNER

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 468

11/01/2011

Industry Report

Pages: 17

BABY FOOD REVISITED

Provider: G.RESEARCH, LLC

Analyst: GABELLI J

Price: 50.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 469

10/24/2011

Company Report

Pages: 14

Raising our estimates in light of strong Q3 CY11 results and upward revision to management?s guidance

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 470

10/20/2011

Company Report

Pages: 9

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 471

10/19/2011

Company Report

Pages: 11

Third Quarter EPS Up 12%. ABT to Split Into Two Publicly-Traded Companies.

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 472

09/26/2011

Company Report

Pages: 12

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 473

07/26/2011

Company Report

Pages: 13

Raising our CY11 & CY12 estimates in light of upward revision to management?s guidance

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 474

07/26/2011

Company Report

Pages: 4

Dropping Coverage Due to Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 475

07/21/2011

Company Report

Pages: 9

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 476

07/20/2011

Company Report

Pages: 10

Pharmaceuticals and Positive Currency Support Second Quarter Sales Growth

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 477

06/22/2011

Industry Report

Pages: 28

Pharmaceuticals Food For Thought

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 75.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 478

06/21/2011

Industry Report

Pages: 25

Upgrading Global Pharma sector to ?Moderate Outperform?

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 75.00

Research Provided by a Third Party

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 479

06/08/2011

Company Report

Pages: 10

Price: 24.95

Company: Abbott Laboratories

Industry: Large Cap Pharmaceuticals

Record: 480

05/26/2011

Daily Note

Pages: 5

Another Black Eye For An ABT Cholesterol Drug -- We See Modest Financial Risk, But Worries Are Likely To Hurt The Stock For The Time-Being

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 10.00

Research Provided by a Third Party
// eof